NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 74 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11 | -57.7% | 10,272 | +1.2% | 0.00% | – |
Q2 2023 | $26 | -36.6% | 10,146 | 0.0% | 0.00% | – |
Q1 2023 | $41 | -69.2% | 10,146 | -61.6% | 0.00% | – |
Q4 2022 | $133 | -100.0% | 26,446 | -0.1% | 0.00% | -100.0% |
Q3 2022 | $346,000 | +18.9% | 26,462 | +16.5% | 0.00% | – |
Q2 2022 | $291,000 | -16.1% | 22,710 | -0.3% | 0.00% | – |
Q1 2022 | $347,000 | -13.9% | 22,784 | +0.1% | 0.00% | – |
Q4 2021 | $403,000 | -16.2% | 22,764 | -0.5% | 0.00% | -100.0% |
Q3 2021 | $481,000 | -10.4% | 22,872 | -15.9% | 0.00% | 0.0% |
Q2 2021 | $537,000 | -16.1% | 27,207 | +23.7% | 0.00% | 0.0% |
Q1 2021 | $640,000 | -3.9% | 22,000 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $666,000 | +90.3% | 22,000 | 0.0% | 0.00% | – |
Q3 2020 | $350,000 | -19.4% | 22,000 | 0.0% | 0.00% | -100.0% |
Q2 2020 | $434,000 | +60.1% | 22,000 | 0.0% | 0.00% | – |
Q1 2020 | $271,000 | -33.4% | 22,000 | 0.0% | 0.00% | – |
Q4 2019 | $407,000 | +324.0% | 22,000 | +218.8% | 0.00% | – |
Q3 2019 | $96,000 | -5.0% | 6,900 | 0.0% | 0.00% | – |
Q2 2019 | $101,000 | – | 6,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Column Group LLC | 18,136,735 | $19,406,306 | 12.88% |
StepStone Group LP | 1,573,357 | $1,683,492 | 0.38% |
EcoR1 Capital, LLC | 6,435,518 | $6,886,004 | 0.23% |
Euclidean Capital LLC | 1,984,336 | $2,123,240 | 0.23% |
Boxer Capital, LLC | 500,000 | $535,000 | 0.03% |
GSA CAPITAL PARTNERS LLP | 213,676 | $229 | 0.02% |
Jasper Ridge Partners, L.P. | 303,492 | $324,736 | 0.02% |
Carson Advisory Inc. | 15,850 | $16,960 | 0.02% |
CORNERCAP INVESTMENT COUNSEL INC | 51,176 | $54,758 | 0.01% |
Parkwood LLC | 68,314 | $73 | 0.01% |